Assertio Holdings, Inc. (Nasdaq: ASRT) (Assertio), a specialty pharmaceutical company offering differentiated products to patients, and Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology, have announced that they have entered into a definitive agreement pursuant to which Assertio will acquire all outstanding shares of Spectrum in an all-stock and contingent value rights (CVR) transaction.

Latham & Watkins LLP represents Assertio in the transaction with a corporate deal team led by Chicago partners Zachary Judd and Owen Alexander, with associates Michael Magstadt, Autumn Schmidt, and Serena Su. Advice was also provided on public company representation matters by Chicago partners Cathy Birkeland and Jonathan Sarna, with associates Andrew Rutsky and Omeed Valipour; on tax matters by Chicago partner Rene de Vera, with associate Chris Ohlgart; on executive compensation and benefits matters by Chicago partner Benjamin Rosemergy, with associates Jina Davidovich and Joe Gu; on environmental matters by Washington, D.C. partner Julia Hatcher, with associate Andrew Landolfi; on real estate matters by Chicago partner Robert Buday, with associate Karen Ritter; on FDA regulatory matters by Washington, D.C. partner Ben Haas, with associate Seth Olson; on intellectual property matters by San Diego partner Steven Chinowsky and San Diego counsel Darryl Steensma, with associate Robert Yeh; on data privacy matters by Bay Area partner Robert Blamires, with associates Kathryn Parsons-Reponte and Dyllan Brown-Bramble; on healthcare regulatory matters by Bay Area partner Betty Pang, with associates Yanyan Zhou and Leia Gu; on finance matters by Chicago partner Noah Weiss and Chicago counsel Colin O’Regan; on securities matters by Chicago partners Nicholas Siciliano and Heather Waller; and on antitrust matters by Washington, D.C. partner Amanda Reeves, Bay Area counsel Jason Daniels. and Washington, D.C. counsel Britton Davis.